NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback